Page 85 - Mesenchymal Stem cells, Exosomes and vitamins in the fight aginst COVID
P. 85
Pain Physician: August 2020 COVID-19 Special Issue 23:S391-S420
Reduction in myocardial infarct size and recovery of regional systolic function, no increase in LVEF or myocardial perfusion Improvement of 6-minute walking distance (6 months) and decreased hospitalization (2 years). No change in LVEF, LVEDD, or myocardium lesion Reduction in death, MI, need for revascularization. Also reduction of recurrence of MI, and/or rehospitalization for health Improvement in NYHA functional class. Reduction in I
Findings and metabolism. area. failure. end-systolic volumes. hospitalization days. duration.
Follow- Up 4 24 12 6 24 6 12 6
LVEF Impact No No Not assessed Yes - improvement Yes – improvement Yes - improvement Yes - improvement Yes - improvement
Outcome Yes Yes Yes Yes Yes Yes Yes Yes
Condition IHD IHD IHD DCM DCM IHD IHD IHD
Delivery Method IC IC IC IC with CS occlusion IC IV IC IC
Type of Stem Cell BM MNC BM MNC BM MNC BM MNC BM MNC Allo BM MSC BM MNC BM MNC
Number of SCs 172 billion UNK 198 billion 28 million UNK 0.5 or 1.6 or 2.5 million/ kg Not disclosed 400 million
Table 2 con't. MSC therapy studies treating cardiac failure.
BMA (mL) 304 billion cells UNK 50 50–60 UNK NA Not disclosed 80
No. of Patients in Treatment Group 33 10 101 24 71 34 27 39
Type of Study RCT PCT RCT RCT PCT RCT RCT RCT
Year 2006 2006 2006 2006 2008 2009 2009 2009
Author Janssens et al, Lancet 2006; 367:113-121 Huang et al, Zhonghua Xin Xue Guan Bing Za Zhi 2006; 34:111-113 Schächinger et al, Eur Heart J 2006; 27:2775-2783 Seth et al, J Am Coll Cardiol 2006; 48:2350-2351 Chen et al, Saudi Med J 2008; 36:1087-1091 Hare et al, J Am Coll Cardiol 2009; 54:2277-2286 Dill et al, Am Heart J 2009; 157:541-547 Miettinen et al, Heart 2010; 96:362-367
S402 www.painphysicianjournal.com
